IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update
IDE397 Preclinical Pharmacodynamic Data
Complete Suppression (95-100%) of Tumor SDMA in Multiple MTAP-Deleted PDX Models
Tumor SDMA and Tumor Growth Inhibition in NSCLC CDX Model
Deep SDMA Inhibition Observed Across Many PDX Models
SDMA modulation corresponds to TGI
NCI-H838 MTAP-/- CDX Model
Tumor SDMA (% of Vehicle)
100-
9
IDEAYA Data
75-
50-
25-
0
Tumor SDMA (IHC)
TGI
101
T
3
30
IDE397 Dose (mg/kg)
Tumor Growth Inhibition (TGI, %)
15
100
11
-75
-50
-25
Vehicle
30 mg/kg
% Reduction of Tumor SDMA
(by IHC-Score)
100-
80-
60-
40-
20-
TGI (%)- 116
92
79
119
93
68
67
65
47
NSCLC
GASTRIC and ESOPHAGEAL BLADDER
9 of 12 MTAP-/- models evaluated have 80-100% reduction of
tumor SDMA as compared to time-matched vehicle control group
(PDX in vivo models dosed at 30 mg/kg)
gsk
IDEAVA
BIOSCIENCESView entire presentation